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Background: SOCS7 is a member of the suppressor of cytokine signaling family of proteins and is expressed in
skeletal muscle and islets. SOCS7 deficient mice develop islet hyperplasia in the setting of increased insulin
sensitivity and normal glucose tolerance. The objective of this study was to determine if variants in SOCS7 play a
role in variation of glucose and insulin levels and the development of type 2 diabetes (T2DM).
Results: Five SOCS7 tagging SNPs were genotyped in diabetic and nondiabetic Old Order Amish. A case–control
study was performed in T2DM (n = 145) and normal glucose tolerant (n = 358) subjects. Nominal associations were
observed with T2DM and the minor alleles for rs8068600 (P = 0.01) and rs8074124 (P = 0.04); however, only
rs8068600 remained significant after Bonferroni adjustment for multiple comparisons (P = 0.01). Among nondiabetic
Amish (n = 765), no significant associations with glucose or insulin traits including fasting or 2 hour glucose and
insulin from the oral glucose tolerance test, insulin or glucose area under the curve, Matsuda Index or HOMA-IR
were found for any of the SNPs.
Conclusion: In conclusion, genetic variants in the SOCS7 gene do not impact variation in glucose homeostasis
traits and only minimally impact risk of T2DM in the Old Order Amish. Our study was not able to address whether
rare variants that potentially impact gene function might influence T2DM risk.
Keywords: Type 2 diabetes, Genetics, SOCS7 gene, PolymorphismBackground
The suppressor of cytokine signaling (SOCS) proteins
are a family of eight proteins that negatively regulate
cytokine signaling pathways via inhibition of JAK/STAT
signal transduction [1-3]. Expression of SOCS proteins is
induced by proinflammatory cytokines including IL1-
beta, INF-gamma, TNF-alpha, IL-6 and growth hormone
[4-7]. In animal models, SOCS proteins 1 and 3 have
been shown to play a role in insulin signaling and dia-
betes [7-14]; however, less is known about other mem-
bers of the SOCS family and their role in the
development of diabetes. In C57BL/6J mice, SOCS7 is
expressed at highest levels in skeletal muscle, pancreatic* Correspondence: ksilver@medicine.umaryland.edu
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reproduction in any medium, provided the orislets, and brain [15]. SOCS7 deficient mice develop islet
hyperplasia [15,16] and on a mixed C57BL/6J and
129S6/SvEvTac background also experience increased in-
sulin sensitivity as demonstrated by lower glucose levels
and prolonged hypoglycemia during an insulin tolerance
test, and increased glucose clearance during an intraperi-
toneal glucose tolerance test [15]. These data suggest
that SOCS7 plays a role in regulating glucose homeosta-
sis. A proposed molecular mechanism for this regulation
is through SOCS7 targeting of insulin receptor substrate
(IRS) proteins for ubiquitination and proteasomal deg-
radation. This action would decrease insulin signaling,
and thereby, increase insulin resistance. Decreased in-
sulin signaling via decreased IRS levels has also been
proposed as the mechanism whereby SOCS7 affects
islet size [15].
The SOCS7 gene contains 10 exons over a 45 kb re-
gion on human chromosome 17q12. In humans, SOCS7
is expressed diffusely with high levels in testis, ovaries,
spleen, brain and spinal cord and moderate levels inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of the Amish*
Trait T2DM NGT NGT + IGT
(n = 145) (n = 358) (n = 765)
% female 69.7 48.0 52.6
Age (yrs) 65 ± 12 51 ± 11 44.3 ± 14.7
BMI (kg/m2) 30.1 ± 4.0 27.4 ± 4.7 27.0 ± 4.8
% IGT - - 19.1
Age of onset 59 ± 11 - -
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of SOCS7’s role in glucose homeostasis in mice, we hy-
pothesized that variants in SOCS7 might contribute to
variation in glucose and insulin levels as well as the de-
velopment of Type 2 diabetes (T2DM) in humans. To
test this hypothesis, we genotyped a panel of tagging
SNPs in the SOCS7 gene in the Old Order Amish of
Lancaster, Pennsylvania and assessed associations with
T2DM and insulin and glucose related traits.of DM (yrs)
HOMA-IR - 2.5 ± 1.5 2.5 ± 1.4
Fasting Glucose
(mmol/L)
- 5.04 ± 0.42 5.02 ± 0.46
2 hour Glucose
(mmol/L)
- 5.76 ± 1.20 6.21 ± 1.7
Fasting Insulin†
(pmol/L)
- 68.1 (55.6, 86.8) 66.7 (54.9, 86.1)
2 hour Insulin†
(pmol/L)
- 211.8 (126.4, 341.0) 218.8 (128.5, 364.6)
AUC Glucose
(mmol/L)
- 349.2 ± 51.5 359.9 ± 67.2
AUC Insulin†
(pmol/L)
- 761.9 (540.3, 1046.6) 752.1 (525.0, 1046.6)
* mean ± SD unless otherwise indicated.
†median (25th, 75th percentile).Methods
Old Order Amish of Lancaster Pennsylvania
The Old Order Amish are a genetically well-defined
Caucasian founder population. Nearly all of these indi-
viduals share common ancestors insofar as the entire
Amish community of Lancaster County (now numbering
over 30,000 individuals) can be connected into a single
14-generation pedigree [17].
The Amish Family Diabetes Study (AFDS) was initi-
ated in 1995 with the goal of identifying susceptibility
genes for T2DM and related traits. A description of sub-
ject recruitment and the examination protocol has been
previously reported [18]. Briefly, probands with T2DM
and their extended family members were invited to par-
ticipate in the study. After an overnight fast, a 75 gram
oral glucose tolerance test (OGTT) was administered to
all subjects without a prior history of diabetes. Blood
samples were sent for analysis of glucose and insulin
concentrations. Glucose concentrations were assayed
with a Beckman glucose analyzer (Beckman Coulter,
Fullerton, CA) using the glucose oxidase method
(interassay coefficient of variation = 1.52%). Insulin levels
were determined by radioimmunoassay (Linco, St. Louis,
MO) (interassay coefficient of variation = 4.42%).
Criteria for the diagnosis of diabetes were adapted
from American Diabetes Association 1997 recommenda-
tions [19]. Diabetes status was defined by a single fasting
venous plasma glucose level ≥7 mmol/l, a 2 hour OGTT
venous plasma glucose level ≥11.1 mmol/l, current treat-
ment with insulin and/or oral hypoglycemic agents, or
by confirmed diagnosis by a physician. Impaired glucose
tolerance (IGT) status was defined as a 2 hour OGTT
glucose value between 7.8 and 11.1 mmol/L. Normal
glucose tolerance (NGT) was defined as having a fasting
glucose <6.1 mmol/L and a 2 hour OGTT glucose
<7.8 mmol/L. Diabetic subjects with an age at diagnosis
<35 years were reclassified as diabetes status unknown
in order to minimize heterogeneity due to inclusion of
subjects with type 1 diabetes. For the case–control
study, a total of 503 Amish subjects [T2DM (n = 145),
and NGT (n = 358) aged 38 years or older] from the
Amish Family Diabetes Study (AFDS) were included in
the analysis (Table 1).Association studies with glucose homeostasis measures
including fasting glucose, fasting insulin, 2 hour glucose,
2 hour insulin, area under the curve (AUC) glucose,
AUC insulin, HOMA-IR and Matsuda Index were
performed in a larger sample of 765 nondiabetic Amish
subjects that included the 358 NGT subjects described
above, an additional 218 NGT subjects, and 148 IGT
subjects. Area under the curve was calculated using the
trapezoid rule. Homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated according to the
following formula: HOMA-IR = [fasting serum insulin
(mU/L) x fasting plasma glucose (mmol/L)]/22.5 [20].
The Matsuda Index was calculated to assess insulin re-
sistance [21].
All study protocols were approved by the Institutional
Review Board at the University of Maryland School of
Medicine. Informed consent was obtained from each
study participant prior to enrollment.
Genotyping
DNA was extracted from leukocytes for genotyping. We
selected 5 SNPs (from a total of 36 SNPs represented in
HapMap CEU) that tagged SOCS7 and the 5 kb region
upstream and downstream of the gene. These SNPs cap-
tured 100% of common variants (>5%) in HapMap CEU
in the SOCS7 gene at r2 > 0.95 (HapMap Release 36).
Figure 1 shows the locations of these SNPs relative to
the 10 exons and their LD structure. Rs3890580 was ge-
notyped by pyrosequencing (PSQ HS 96MA System;















































Figure 1 SOCS7 gene structure and genotyped SNPs. The 5 SNPs
are represented by the numbers 1–5 above the correlation matrix. The
numbers within each box of the correlation matrix represent pairwise
r2 value between SNPs.
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manufacturer’s protocol. Rs4300700 was genotyped
using either TaqMan SNP Genotyping Assays (Applied
Biosystems; Foster City, CA) according to the manufac-
turer’s protocol or by dideoxy sequencing on an ABI
3730xl sequencer. Rs3935220, rs8068600 and rs8074124
were genotyped by either pyrosequencing or TaqMan.
At least 5% duplicate samples were included to deter-
mine genotype concordance rates within the same plat-
form and between different genotyping platforms, which
were 95-100%. Discordant samples were excluded from
analysis.
Genome wide association study (GWAS) SOCS7 SNP
association data was downloaded from the Meta-
Analyses of Glucose and Insulin-related traits Consor-
tium (MAGIC) web site (http://www.magicinvestigators.
org/downloads/) for HOMA-IR, fasting insulin, fasting
glucose and 2 hour glucose [22,23]. The National Hu-
man Genome Research Institute (NHGRI) database
(www.genome.gov/gwastudies) was used to search forTable 2 Allele frequencies and results of association analysis
SNP name Major/minor allele Minor allele frequency Mats
P value
rs4300700 G/A 0.08 0.98
rs3935220 G/C 0.09 0.31
rs8068600 G/C 0.17 0.25
rs8074124 T/C 0.22 0.46
rs3890580 T/A 0.20 0.45SOCS7 SNPs associated with T2DM as well as glucose
and insulin related traits [24].
Statistical analysis
Before analysis, Amish genotypes were checked for
Mendelian consistency using the PedCheck software
program [25] in the extended Amish pedigree. A small
number of Mendelian errors (<1.5% of genotypes) were
either resolved or removed before analysis. Observed ge-
notypes for all SNPs were tested for fit with those
expected under Hardy-Weinberg equilibrium using the
Chi square test; all genotype distributions conformed to
Hardy-Weinberg expectations.
Quantitative trait means were estimated according to
SOCS7 genotypes in the 765 nondiabetic Amish subjects.
To account for the relatedness among family members,
the measured genotype approach was used [26] in which
we estimated the likelihood of specific genetic models
given the pedigree structure. Parameter estimates were
obtained by maximum likelihood methods, and the sig-
nificance of association was tested by likelihood ratio
tests. Analyses were performed using recessive, domin-
ant and additive models. Within each model, we simul-
taneously estimated the effects of age and sex, and age,
sex and body mass index (BMI). Quantitative trait ana-
lyses were conducted using the SOLAR software pro-
gram [27]. To account for the multiple SNPs tested, we
considered a P-value of 0.01 to be statistically significant.
Analysis of the diabetes trait was made using the dichot-
omous trait extension to the SOLAR software program,
which employs a threshold model to assess the effect of
genotype on the binary outcome.
Results
Characteristics of the Amish subjects are presented in
Table 1. To determine if SNPs in the SOC7 gene con-
tribute to the development of T2DM, we employed a
case–control analysis utilizing 145 T2DM cases and 358
NGT controls from the AFDS. Subjects with T2DM were
older, had a higher BMI and were more likely to be fe-
male. Nominal associations with T2DM were found for
the minor allele for rs8068600 (P = 0.01) and rs8074124
(P = 0.04) (Table 2, Additional file 1: Table S1); however,uda index Fasting glucose Diabetes vs. control
β coefficient P value β coefficient P value Odds ratio
−0.006 0.96 0.043 0.84 0.96
0.227 0.26 −0.887 0.99 1.00
0.236 0.98 −0.021 0.01 1.59
0.133 0.40 −0.524 0.04 1.39
0.144 0.19 −0.864 0.15 1.27
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rs8068600 met the Bonferroni-adjusted threshold for
statistical significance (P = 0.01). No significant or nom-
inally significant (P < 0.05) associations with glucose or
insulin traits including fasting or 2 hour glucose and in-
sulin from the OGTT, Insulin AUC, Glucose AUC,
Matsuda Index or HOMA-IR were found for any of the
SNPs in the Amish after adjustment for age and sex.
Similar results were found when BMI was included in
the model. Data from the MAGIC GWAS identified a
nominal association of rs4300700 with ln fasting insulin
(P = 0.01). No additional associations were found in the
MAGIC data for SOCS7 tagging SNPs for ln fasting in-
sulin, fasting glucose, 2 hour glucose or HOMA-IR
[22,23]. Review of the NHGRI GWAS database did not
reveal any SOCS7 SNP associations with T2DM or
other glucose homeostasis traits; however, SNPs in-
cluded in the database are limited to those with P-values
<1.0 × 10-5 [24].
Linkage disequilibrium (LD) analysis in the Amish re-
vealed some LD among most of the SOCS7 SNPs (r2 = 0-
0.73; see Figure 1). The closest genes 5′ of SOCS7 are
GPR179 (8.3 kb) and MRPL45 (28.9 kb) and the closest
gene 3′ is SNIP (178.3 kb). None of these genes are in
the same LD block as the SOCS7 gene.
Discussion and conclusion
Based on studies in mice and other members of the
SOCS family of proteins, SOCS7 is an excellent candi-
date gene for regulation of glucose homeostasis traits
and T2DM as a mutation in the SOCS7 gene causing de-
creased or absent function of the SOCS7 protein would
be expected to improve insulin sensitivity and decrease
the risk of T2DM while an activating mutation in the
SOCS7 gene would be expected to increase insulin re-
sistance and the risk of T2DM [12,14,15,28,29]. Despite
genotyping SNPs in and adjacent to the SOCS7 gene,
SNP genotype did not significantly impact risk of
T2DM, measures of insulin resistance or glucose levels
after adjustment for multiple comparisons. These results
are consistent with findings in MAGIC and other
GWAS [22-24]. Only one other candidate gene study
has examined the role of genetic variation in the SOCS7
gene with measures of insulin resistance. In contrast to
our study, Tellechea et al. found an association between
rs8074124 and HOMA-IR (P = 0.018) in 780 men with
European ancestry seen at the University of Buenos
Aires [30]. Differences in results may be due to the in-
clusion of women in our study as well as differences in
recruitment strategies as the University of Buenos Aires
population was recruited from the Department of
Haemotherapy.
While the number of subjects included in our study
was relatively small compared to those found in genomewide association studies, our sample of 765 subjects did
none-the-less provide 80% power to detect an associ-
ation that accounted for as little as 1.5% of the total vari-
ance in glucose and insulin homeostasis traits. One
limitation of our study is that we were underpowered to
detect modest effect sizes for T2DM in the case–control
study as our sample provided 80% power to detect odds
ratios of 1.6 to 1.8. While it is possible that SOCS7 plays
a role in T2DM and related glucose homeostasis traits
in other populations, this scenario seems unlikely as
many genetic findings in the Amish are similar to those
found in the outbreed Caucasian population [31-33].
Furthermore, in SOCS7 SNPs found on the DNA micro-
array chips used for T2DM and glucose homeostasis
GWAS, no significant associations have been reported
with these SNPs or other SNPs in the region of the
SOCS7 gene. Additionally, in studies by MAGIC, only
one nominally associated SNP (rs4300700) was identified
which is consistent with our findings in the Amish of a
very limited to no impact of SOCS7 on risk of T2DM or
variation in glucose homeostasis traits [22]. Another
limitation of our study is the higher number of female
subjects in the T2DM group compared to the NGT and
NGT + IGT groups. This difference may be due to selec-
tion bias related possibly to women being more health
conscious and more willing to take advantage of the
screening done as part of the study.
In summary, genetic variation in the SOCS7 gene does
not significantly impact glucose homeostasis traits or
risk of T2DM in the Old Order Amish of Lancaster
Pennsylvania.Additional file
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